Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

Figure 2

Pattern of scan results for florbetapir and florbenazine for subjects in the 4 diagnostic groups. The vertical line shows the florbenazine SUVr cut-off (2.12) that agrees best with expert visual interpretation. The horizontal line (SUVr = 1.1) marks the published quantitative cut-off for florbetapir. The distribution of imaging patterns (proportion of subjects in each quadrant) differed significantly between groups (chi2 = 41.7, p <0.001) In the AD, PD and HC groups, there was one dominant pattern (for example, all of the AD cases had positive florbetapir scans and negative florbenazine scans). While VMAT2 binding was low in the DLB group on average, three subjects had SUVr values above the cut-off, and no single imaging pattern was observed in a majority of DLB patient.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us